Marjorie Uhalde
Family Medicine · Reno, NVNPI 1669568515
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.8% of the total across 127 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 21.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $1,187 and has fallen 98.3% since, to $20 in 2023.
Across 127 payments — averaging $15.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amarin Pharma, Inc.$435
- Amgen$303
- Boehringer Ingelheim$221
- AstraZeneca$195
- GSK$183
- Merck$95
- plus $583 from 18 others
What the payments were for
- Food & beverage$1,97298%
- Education$442%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amarin Pharma, Inc. | 38 | $435 |
| Amgen | 13 | $303 |
| Boehringer Ingelheim | 14 | $221 |
| AstraZeneca | 10 | $195 |
| GSK | 11 | $183 |
| Merck | 6 | $95 |
| AbbVie | 4 | $68 |
| Pfizer | 3 | $54 |
| Lilly USA, LLC | 3 | $52 |
| Eisai Inc. | 3 | $47 |
| Johnson & Johnson | 3 | $47 |
| Sanofi-aventis U.S. LLC | 3 | $47 |
| Therapeuticsmd, Inc. | 2 | $38 |
| Novo Nordisk | 2 | $37 |
| Astellas Pharma US Inc | 2 | $36 |
| Boston Scientific | 2 | $32 |
| Lucid Diagnostics Inc. | 1 | $20 |
| Ironwood Pharmaceuticals, Inc | 1 | $17 |
| Collegium Pharmaceutical, Inc. | 1 | $17 |
| Ultragenyx Pharmaceutical Inc. | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Regeneron Healthcare Solutions, Inc. | 1 | $15 |
| Abbott | 1 | $12 |
| Sanofi Pasteur Inc. | 1 | $12 |
How this compares
$2,016 in reported general payments places this provider in the 80th percentile of 902 family medicine providers in Nevada.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cefdinir | 12 | $1,114 |
| Topiramate | 18 | $730 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 13 | $421 |
| Levothyroxine Sodium | 28 | $400 |
| Quetiapine Fumarate | 27 | $371 |
| Montelukast Sodium | 18 | $301 |
| Carvedilol | 13 | $180 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Reno
- Bayo Curry-WinchellReno$74K
- Catherine McCarthyReno$68K
- Francisco DofelizReno$30K
- Michael ObrienReno$18K
- James McLennanReno$16K
- Jeremy BearfieldReno$15K
- Ricardo GonzalezReno$11K
- Jennifer HornbackReno$11K
- Ambika UppuReno$11K
- Vance AlmReno$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.